The US healthcare sector may face rising costs as a result of a 25% tariff and additional penalties on Indian imports, including pharmaceuticals and medical devices. Experts warn of declining profits, stalled R&D, and shifting global trade dynamics.
(Source: unsplash)
Healthcare costs in the US will increase following the imposition of a sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from the pharmaceuticals and medical devices industry said on Thursday.
President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment.
Profits for Indian pharmaceutical firms may decline, and research and development may stagnate. However, for the medical devices sector, as long as the gap between the duty on China and India is over 15-20 per cent, there are positive prospects for exports to the US, according to experts.
By continuing you agree to our Privacy Policy & Terms & Conditions
